Stocktwits on MSN2d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving UpShares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
HealthDay on MSN3d
Sarepta’s Gene Therapy Under Scrutiny After Patient DeathA patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Wall Street's major averages closed in the green on Friday, and the benchmark S&P 500 (SP500) snapped a four-week losing streak after U.S. President Donald Trump said there might be some "flexibility" ...
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...
In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback